FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	<b>OF CHANGES</b>	IN BENEFICIAL	OWNERSHIP

l	OMB APPRO	OVAL					
	OMB Number:	3235-0287					
	Estimated average burden						
ı	hours nor resnance.	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fleming Alison B				<u>C(</u>	2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC [ COLL ]								eck all app Direc	licable) tor er (give title	ig Pers	son(s) to Issi 10% Ow Other (s	ner	
(Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 11/08/2019								belov	ow) below) Chief Technology Officer				
(Street) STOUGHTON MA 02072  (City) (State) (Zip)				_   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Lin	e) <mark>X</mark> Form Form	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(Oity)	(0			n-Deri	vativ	- Sec	·urit	ies Ac	nuired	Dis	enosed o	f or Re	neficial	ly Owne	ď			
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Day			action	tion 2A. Deemed Execution Dat		med on Date,	3. Transaction Code (Instr		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a		l (A) or	5. Amount Securities Beneficially Owned Foll		Form (D) o	m: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Report Transa (Instr.	etion(s) and 4)			(Instr. 4)	
Common Stock 11/08/2				3/2019	019			М		25,000	A	\$5.7	9	8,556		D		
Common Stock 11/08/2			3/2019	2019		S		25,000	D	\$19.44	(1) 7	3,556		D				
		٦	Table II -								osed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		(Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	Code (Ins				6. Date Exercisable a Expiration Date (Month/Day/Year)		te	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price o Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	de V		(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to	\$5.73	11/08/2019			M			25,000	(2)		03/19/2025	Common Stock	25,000	\$0	35,37	8	D	

## **Explanation of Responses:**

## Remarks:

/s/ Paul Brannelly as Attorney-In-Fact For Alison B. Fleming

11/13/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.10 to \$19.71, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth

<sup>2.</sup> The option was fully vested and exercisable as of November 8, 2019.